186 related articles for article (PubMed ID: 16952645)
1. E-cadherin protein expression predicts prostate cancer salvage radiotherapy outcomes.
Ray ME; Mehra R; Sandler HM; Daignault S; Shah RB
J Urol; 2006 Oct; 176(4 Pt 1):1409-14; discussion 1414. PubMed ID: 16952645
[TBL] [Abstract][Full Text] [Related]
2. Salvage radiotherapy for isolated prostate specific antigen increase after radical prostatectomy: evaluation of prognostic factors and creation of a prognostic scoring system.
Buskirk SJ; Pisansky TM; Schild SE; Macdonald OK; Wehle MJ; Kozelsky TF; Collie AC; Ferrigni RG; Myers RP; Prussak KA; Heckman MG; Crook JE; Parker AS; Igel TC
J Urol; 2006 Sep; 176(3):985-90. PubMed ID: 16890677
[TBL] [Abstract][Full Text] [Related]
3. Outcome of salvage radiotherapy for biochemical failure after radical prostatectomy with or without hormonal therapy.
Cheung R; Kamat AM; de Crevoisier R; Allen PK; Lee AK; Tucker SL; Pisters L; Babaian RJ; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):134-40. PubMed ID: 16111581
[TBL] [Abstract][Full Text] [Related]
4. Long-term results and predictive factors of three-dimensional conformal salvage radiotherapy for biochemical relapse after prostatectomy.
Neuhof D; Hentschel T; Bischof M; Sroka-Perez G; Hohenfellner M; Debus J
Int J Radiat Oncol Biol Phys; 2007 Apr; 67(5):1411-7. PubMed ID: 17275204
[TBL] [Abstract][Full Text] [Related]
5. E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology.
Rubin MA; Mucci NR; Figurski J; Fecko A; Pienta KJ; Day ML
Hum Pathol; 2001 Jul; 32(7):690-7. PubMed ID: 11486167
[TBL] [Abstract][Full Text] [Related]
6. Postoperative prostate-specific antigen velocity independently predicts for failure of salvage radiotherapy after prostatectomy.
King CR; Presti JC; Brooks JD; Gill H; Spiotto MT
Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1472-7. PubMed ID: 17935902
[TBL] [Abstract][Full Text] [Related]
7. Long-term salvage radiotherapy outcome after radical prostatectomy and relapse predictors.
Brooks JP; Albert PS; Wilder RB; Gant DA; McLeod DG; Poggi MM
J Urol; 2005 Dec; 174(6):2204-8, discussion 2208. PubMed ID: 16280764
[TBL] [Abstract][Full Text] [Related]
8. Pre-operative percent free PSA predicts clinical outcomes in patients treated with radical prostatectomy with total PSA levels below 10 ng/ml.
Shariat SF; Abdel-Aziz KF; Roehrborn CG; Lotan Y
Eur Urol; 2006 Feb; 49(2):293-302. PubMed ID: 16387412
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen velocity accurately predicts response to salvage radiotherapy in men with biochemical relapse after radical prostatectomy.
Patel R; Lepor H; Thiel RP; Taneja SS
Urology; 2005 May; 65(5):942-6. PubMed ID: 15882728
[TBL] [Abstract][Full Text] [Related]
10. Improved outcomes with higher doses for salvage radiotherapy after prostatectomy.
King CR; Spiotto MT
Int J Radiat Oncol Biol Phys; 2008 May; 71(1):23-7. PubMed ID: 18207668
[TBL] [Abstract][Full Text] [Related]
11. Achieving an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome--results of a retrospective study.
Wiegel T; Lohm G; Bottke D; Höcht S; Miller K; Siegmann A; Schostak M; Neumann K; Hinkelbein W
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1009-16. PubMed ID: 18963539
[TBL] [Abstract][Full Text] [Related]
12. Expression of p21 cell cycle protein is an independent predictor of response to salvage radiotherapy after radical prostatectomy.
Rigaud J; Tiguert R; Decobert M; Hovington H; Latulippe E; Laverdiere J; Larue H; Lacombe L; Fradet Y
Prostate; 2004 Feb; 58(3):269-76. PubMed ID: 14743466
[TBL] [Abstract][Full Text] [Related]
13. Obesity and risk of biochemical failure for patients receiving salvage radiotherapy after prostatectomy.
King CR; Spiotto MT; Kapp DS
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1017-22. PubMed ID: 18707829
[TBL] [Abstract][Full Text] [Related]
14. Preoperative p53, bcl-2, CD44 and E-cadherin immunohistochemistry as predictors of biochemical relapse after radical prostatectomy.
Brewster SF; Oxley JD; Trivella M; Abbott CD; Gillatt DA
J Urol; 1999 Apr; 161(4):1238-43. PubMed ID: 10081877
[TBL] [Abstract][Full Text] [Related]
15. Salvage hypofractionated radiotherapy for biochemically recurrent prostate cancer after radical prostatectomy.
Wong GW; Palazzi-Churas KL; Jarrard DF; Paolone DR; Graf AK; Hedican SP; Wegenke JD; Ritter MA
Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):449-55. PubMed ID: 17869014
[TBL] [Abstract][Full Text] [Related]
16. Locally recurrent prostate cancer after initial radiation therapy: a comparison of salvage radical prostatectomy versus cryotherapy.
Pisters LL; Leibovici D; Blute M; Zincke H; Sebo TJ; Slezak JM; Izawa J; Ward JF; Scott SM; Madsen L; Spiess PE; Leibovich BC
J Urol; 2009 Aug; 182(2):517-25; discussion 525-7. PubMed ID: 19524984
[TBL] [Abstract][Full Text] [Related]
17. Low pre-radiotherapy prostate-specific antigen level is a significant predictor of treatment success for postoperative radiotherapy in patients with prostate cancer.
Sasaki T; Nakamura K; Shioyama Y; Ohga S; Toba T; Urashima Y; Yoshitake T; Terashima H; Koga H; Naito S; Noma H; Komatsu K; Yamaguchi A; Hiratsuka Y; Hirano T; Hanada K; Abe M; Fujisawa Y; Honda H
Anticancer Res; 2006; 26(3B):2367-74. PubMed ID: 16821618
[TBL] [Abstract][Full Text] [Related]
18. Sooner or later? Outcome analysis of 431 prostate cancer patients treated with postoperative or salvage radiotherapy.
Jereczek-Fossa BA; Zerini D; Vavassori A; Fodor C; Santoro L; Minissale A; Cambria R; Cattani F; Garibaldi C; Serafini F; Matei VD; de Cobelli O; Orecchia R
Int J Radiat Oncol Biol Phys; 2009 May; 74(1):115-25. PubMed ID: 19004572
[TBL] [Abstract][Full Text] [Related]
19. Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer.
Pisansky TM; Kozelsky TF; Myers RP; Hillman DW; Blute ML; Buskirk SJ; Cheville JC; Ferrigni RG; Schild SE
J Urol; 2000 Mar; 163(3):845-50. PubMed ID: 10687990
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era.
Boorjian SA; Thompson RH; Siddiqui S; Bagniewski S; Bergstralh EJ; Karnes RJ; Frank I; Blute ML
J Urol; 2007 Sep; 178(3 Pt 1):864-70; discussion 870-1. PubMed ID: 17631342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
